Combined effects of exercise and immuno-chemotherapy treatments on tumor growth in MC38 colorectal cancer-bearing mice.

acute exercise cancer immunotherapy colorectal cancer immune cell immune check point inhibitor

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 10 01 2024
accepted: 29 01 2024
medline: 1 3 2024
pubmed: 1 3 2024
entrez: 1 3 2024
Statut: epublish

Résumé

Acute exercise induces transient modifications in the tumor microenvironment and has been linked to reduced tumor growth along with increased infiltration of immune cells within the tumor in mouse models. In this study, we aimed to evaluate the impact of acute exercise before treatment administration on tumor growth in a mice model of MC38 colorectal cancer receiving an immune checkpoint inhibitor (ICI) and chemotherapy. Six-week-old mice injected with colorectal cancer cells (MC38) were randomized in 4 groups: control (CTRL), immuno-chemotherapy (TRT), exercise (EXE) and combined intervention (TRT/EXE). Both TRT and TRT-EXE received ICI: anti-PD1-1 (1 injection/week) and capecitabine + oxaliplatin (5 times a week) for 1 week (experimentation 1), 3 weeks (experimentation 2). TRT-EXE and EXE groups were submitted to 50 minutes of treadmill exercise before each treatment administration. Over the protocol duration, tumor size has been monitored daily. Tumor growth and microenvironment parameters were measured after the intervention on Day 7 (D7) and Day 16 (D16). From day 4 to day 7, tumor volumes decreased in the EXE/TRT group while remaining stable in the TRT group (p=0.0213). From day 7 until day 16 tumor volume decreased with no significant difference between TRT and TRT/EXE. At D7 the TRT/EXE group exhibited a higher total infiltrate T cell (p=0.0118) and CD8+ cytotoxic T cell (p=0.0031). At D16, tumor marker of apoptosis, vascular integrity and inflammation were not significantly different between TRT and TRT/EXE. Our main result was that acute exercise before immuno-chemotherapy administration significantly decreased early-phase tumor growth (D0 to D4). Additionally, exercise led to immune cell infiltration changes during the first week after exercise, while no significant molecular alterations in the tumor were observed 3 weeks after exercise.

Identifiants

pubmed: 38426110
doi: 10.3389/fimmu.2024.1368550
pmc: PMC10902641
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1368550

Informations de copyright

Copyright © 2024 Gouez, Rébillard, Thomas, Beaumel, Matera, Gouraud, Orfila, Martin, Pérol, Chaveroux, Chirico, Dumontet, Fervers and Pialoux.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Manon Gouez (M)

Prevention Cancer Environment Department, Léon Bérard Cancer Center, Lyon, France.
Team Atherosclerosis, Thrombosis and Physical Activity, LIBM EA7424, Université Claude Bernard Lyon 1, Université de Lyon, Faculty of Medicine, Lyon, France.
Inserm, U1296 Unit, "Radiation: Defense, Health and Environment", Centre Léon Bérard, Lyon, France.

Amélie Rébillard (A)

Movement, Sport, and Health Sciences Laboratory, EA 1274, Université Rennes 2, ENS Rennes, Bruz, France.
Institut Universitaire de France, Paris, France.

Amandine Thomas (A)

Team Atherosclerosis, Thrombosis and Physical Activity, LIBM EA7424, Université Claude Bernard Lyon 1, Université de Lyon, Faculty of Medicine, Lyon, France.

Sabine Beaumel (S)

CRCL INSERM 1052/CNRS 5286, University of Lyon, Hospices Civils de Lyon, Lyon, France.

Eva-Laure Matera (EL)

CRCL INSERM 1052/CNRS 5286, University of Lyon, Hospices Civils de Lyon, Lyon, France.

Etienne Gouraud (E)

Team Atherosclerosis, Thrombosis and Physical Activity, LIBM EA7424, Université Claude Bernard Lyon 1, Université de Lyon, Faculty of Medicine, Lyon, France.

Luz Orfila (L)

Movement, Sport, and Health Sciences Laboratory, EA 1274, Université Rennes 2, ENS Rennes, Bruz, France.

Brice Martin (B)

Movement, Sport, and Health Sciences Laboratory, EA 1274, Université Rennes 2, ENS Rennes, Bruz, France.

Olivia Pérol (O)

Prevention Cancer Environment Department, Léon Bérard Cancer Center, Lyon, France.
Inserm, U1296 Unit, "Radiation: Defense, Health and Environment", Centre Léon Bérard, Lyon, France.

Cédric Chaveroux (C)

CRCL INSERM 1052/CNRS 5286, University of Lyon, Hospices Civils de Lyon, Lyon, France.

Erica N Chirico (EN)

Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ, United States.

Charles Dumontet (C)

CRCL INSERM 1052/CNRS 5286, University of Lyon, Hospices Civils de Lyon, Lyon, France.

Béatrice Fervers (B)

Prevention Cancer Environment Department, Léon Bérard Cancer Center, Lyon, France.
Inserm, U1296 Unit, "Radiation: Defense, Health and Environment", Centre Léon Bérard, Lyon, France.

Vincent Pialoux (V)

Team Atherosclerosis, Thrombosis and Physical Activity, LIBM EA7424, Université Claude Bernard Lyon 1, Université de Lyon, Faculty of Medicine, Lyon, France.

Classifications MeSH